| Patents for C12P 21 - Preparation of peptides or proteins (112,499) |
|---|
| 01/11/2011 | US7867498 comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides; for use in treatment and prevention of plasmodial infection; genetic vaccines; for immunization |
| 01/11/2011 | US7867493 for preventing and treating cancer; kits; Prolactin receptor (PRLR) |
| 01/11/2011 | US7867491 hybrid Fc; useful as a carrier of biologically active molecules |
| 01/11/2011 | US7867482 treating cancer responsive to interferon alpha therapy; the protein is non-naturally occurring and has enhanced anti-viral and anti-proliferative activity in comparison to human interferon alpha 2b (HuIFN- alpha 2b) |
| 01/11/2011 | CA2429303C Promoter for the functional characterization of g protein-coupled receptors in the yeast saccharomyces cerevisiae |
| 01/11/2011 | CA2409305C In vitro evolution of nucleic acids and encoded polypeptide |
| 01/06/2011 | WO2011002494A1 Use of immunoglobulin heavy and light chains or fragments therof to bind to aggregated amyloidogenic proteins |
| 01/06/2011 | WO2011001882A1 Flagellin mutant capable of effectively inducing protective capability on infection by pseudomonas aeruginosa |
| 01/06/2011 | WO2011001432A1 Novel antibodies and their uses in therapeutic and diagnostic methods |
| 01/06/2011 | WO2011000933A2 Enhanced phytase variants |
| 01/06/2011 | WO2011000929A1 Neurotoxins exhibiting shortened biological activity |
| 01/06/2011 | WO2011000523A1 Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes |
| 01/06/2011 | WO2010132659A3 Anti-human cd52 immunoglobulins |
| 01/06/2011 | WO2010129917A3 Anti-cd100 antibodies and methods for using the same |
| 01/06/2011 | WO2010124009A3 Fully human anti-vegf antibodies and methods of using |
| 01/06/2011 | US20110004949 Immunoglobulin 1 |
| 01/06/2011 | US20110004948 Immunoglobulin 2 |
| 01/06/2011 | US20110003736 Pesticidal proteins |
| 01/06/2011 | US20110003729 Novel fungal protease and use thereof |
| 01/06/2011 | US20110003383 Antibodies to ht5gj57 |
| 01/06/2011 | US20110003340 Synthetic genes for plant gums and other hydroxyproline-rich proteins |
| 01/06/2011 | US20110003339 Pathogenic Escherichia Coli Associated Protein |
| 01/06/2011 | US20110003338 Antibodies with enhanced adcc function |
| 01/06/2011 | US20110003337 Immunoglobulin compositions and methods of producing same |
| 01/06/2011 | US20110003336 Methods for Increasing the Therapeutic Efficacy of Immunoglobulin G Class 3 (IgG3) Antibodies |
| 01/06/2011 | US20110003335 Methods for prognosing the status of tumor patients |
| 01/06/2011 | US20110003334 Method for producing a cell capable of high-yield production of heteroproteins |
| 01/06/2011 | US20110003333 Method for Increasing Expression Yield of a Protein of Interest |
| 01/06/2011 | US20110003332 Recombinantly modified plasmin |
| 01/06/2011 | US20110003319 Transgenic Trasnchromosomal Rodents for Making Human Antibodies |
| 01/06/2011 | US20110003276 Blood separation and concentration system |
| 01/06/2011 | US20110002957 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 01/06/2011 | US20110002955 Anti-obese immunogenic hybrid polypeptides and anti-obese vaccine composition comprising the same |
| 01/06/2011 | US20110002942 Engineered Anti-IL-23 Antibodies |
| 01/06/2011 | US20110002937 Method of making hybrid cells that express useful antibodies |
| 01/06/2011 | US20110002929 Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| 01/06/2011 | US20110002927 Antigen-binding polypeptides against cartilage degeneration |
| 01/06/2011 | US20110002926 Hepatitis c virus antibodies |
| 01/06/2011 | US20110002917 Antibody constant domain regions and uses thereof |
| 01/06/2011 | US20110002910 Therapeutic agents comprising pro-apoptotic proteins |
| 01/06/2011 | CA2767039A1 Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes |
| 01/06/2011 | CA2766770A1 Novel antibodies and their uses in therapeutic and diagnostic methods |
| 01/06/2011 | CA2766704A1 Enhanced phytase variants |
| 01/06/2011 | CA2763692A1 Neurotoxins exhibiting shortened biological activity |
| 01/05/2011 | EP2270504A2 Techniques for growth and differentiation of human pluripotent stem cells |
| 01/05/2011 | EP2270171A2 Haemophilus influenzae antigens and corresponding DNA fragments |
| 01/05/2011 | EP2270152A1 Expression system using mammalian beta-actin promoter |
| 01/05/2011 | EP2270150A2 Method for controlling the activity of immunologically functional molecule |
| 01/05/2011 | EP2270149A2 Method for controlling the activity of immunologically functional molecule |
| 01/05/2011 | EP2270148A2 Method for controlling the activity of immunologically functional molecule |
| 01/05/2011 | EP2270147A2 Method for controlling the activity of immunologically functional molecule |
| 01/05/2011 | EP2270145A1 Novel protein capable of binding to hyaluronic acid, and method for measurement of hyaluronic acid using the same |
| 01/05/2011 | EP2270138A1 Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes |
| 01/05/2011 | EP2270052A2 Antibodies to OPGL |
| 01/05/2011 | EP2270051A2 Antibody specific for human PD-1 and CD3 |
| 01/05/2011 | EP2270049A2 Recombinant anti-interleukin-9-antibody |
| 01/05/2011 | EP2270047A2 Anti-C5 antibodies and their therapeutic uses |
| 01/05/2011 | EP2270046A2 Methods and compositions for the treatment of hemolysis-associated diseases |
| 01/05/2011 | EP2270031A2 Heterologous expression of neisserial proteins |
| 01/05/2011 | EP2270030A2 Heterologous expression of Neisserial proteins |
| 01/05/2011 | EP2270027A1 Polypeptides having brain-localizing activity and uses thereof |
| 01/05/2011 | EP2269634A2 Antigenic polypeptides |
| 01/05/2011 | EP2269471A1 Method for production of defatted soymilk peptide |
| 01/05/2011 | EP2268157A1 Mixture of peptide-bound tryptophan and polypeptide-bound tryptophan |
| 01/05/2011 | EP1957660B1 Materials and methods to increase peptide chain expression |
| 01/05/2011 | EP1922334B1 Tumor-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules and related anti-cancer vaccine |
| 01/05/2011 | EP1689869B1 Recombinant microorganism |
| 01/05/2011 | EP1546182B1 Compositions and methods for the diagnosis and treatment of tumor |
| 01/05/2011 | EP1463806B1 Novel cyclooxygenase variants and methods of use |
| 01/05/2011 | EP1301202B1 Genetically-engineered mhc molecules |
| 01/05/2011 | EP1294769B1 Antibodies that immunospecifically bind to blys |
| 01/05/2011 | EP0815129B1 Ingap protein involved in pancreatic islet neogenesis |
| 01/05/2011 | CN101939443A Modified leptin polypeptides and their uses |
| 01/05/2011 | CN101935352A Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies |
| 01/05/2011 | CN101935351A Human vascuoar endothelial cell growth factor analogue |
| 01/05/2011 | CN101935349A Humanized monoclonal antibody against human vascular endothelial growth factor and preparation and application thereof |
| 01/05/2011 | CN101935342A Moth orchid development B gene-PhAP3 coded sequence and application thereof |
| 01/05/2011 | CN101935341A Polypeptide with activity of inhibiting beta-lactamase and preparation method and application thereof |
| 01/05/2011 | CN101508999B Recombinant toxoplasma protein and uses thereof |
| 01/05/2011 | CN101508994B Gene optimization and high-efficiency expression of recombinant human interferon a2b |
| 01/05/2011 | CN101235408B Method for preparing Lactoferrins antibiotic peptide by enzyme method |
| 01/04/2011 | US7863503 Glyphosate-N-acetyltransferase (GAT) genes |
| 01/04/2011 | US7863433 Nucleic acids encoding a G-protein coupled receptor involved in sensory transduction |
| 01/04/2011 | US7863424 Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma |
| 01/04/2011 | US7863423 polynucleotides and polypeptides which are under-expressed in cancer and dysplasia delivered therapeutically to reduce the abnormal characteristics of cancer and dysplastic cells |
| 01/04/2011 | US7863418 T cell immune response cDNA 7 (TIRC7) protein for use in treatment of organ transplantation rejection, tumor, autoimmune and/or allergic disorders |
| 01/04/2011 | US7863042 Fucose transporter |
| 01/04/2011 | US7863031 Recombinant hydrolase for use in enhancing/;improving quality of animal feeds and foodstuffs |
| 01/04/2011 | US7863030 Regio- and enantioselective alkane hydroxylation with modified cytochrome P450 |
| 01/04/2011 | US7863020 Using transgenic yeast as bioreactor for generation of sialylated glycoprotein |
| 01/04/2011 | US7863019 Propagating interleukin-15 specific monoclonal antibody for use as tool in controllig immune response |
| 01/04/2011 | US7863018 Nucleotide sequences coding colony stimulating factor for treating cancers, infectious diseases, cardiopathies, inflammatory diseases and to support organ transplants |
| 01/04/2011 | US7863016 Nucleotide sequences coding colony stimulating factor for treating cancers, infectious diseases, cardiopathies, inflammatory diseases and to support organ transplants |
| 01/04/2011 | US7863015 Apparatus for concurrent in vitro protein synthesis of multiple proteins; cell-free translation |
| 01/04/2011 | US7863009 Mutants of the factor VII-activating protease and detection methods using specific antibodies |
| 01/04/2011 | US7863006 Monoclonal antibody for use in detection of spongiform encephalopathy and brain disorders |
| 01/04/2011 | US7862994 Preventing fusion of virus and preferential cells; incubate cells with genetically engineered viral particles and viricide, detect reduction in emission energy, reduction in emission indicates prevention of viral fusion and infection |
| 01/04/2011 | US7862827 Combination neisserial compositions |
| 01/04/2011 | US7862820 Immunoglobulin chimeric monomer-dimer hybrids |
| 01/04/2011 | US7862817 Kit to treat ErbB2-expressing cancer in patient; humanized version of monoclonal antibody 2C4; immunoconjugate of humanized antibody conjugated with a cytotoxic agent; patient produces a greater than normal level of ErbB ligand epidermal growth factor, transforming growth factor alpha |